Illumina Inc., of San Diego, said that it and its subsidiary, Verinata Health Inc., of Redwood City, Calif., filed a patent infringement suit against Genoma SA, of Geneva Switzerland, in the Federal Patent Court in Switzerland. Illumina is seeking all available remedies, including damages and injunctive relief. The patents asserted are european patent (CH) 2 183 693 B1, european patent (CH) 0 994 963 B2, european patent (CH) 1 981 995 B1, and european patent (CH) 2 514 842. The patents are directed to using cell-free fetal DNA for non-invasive prenatal testing (NIPT). The suit accuses Genoma's Tranquility NIPT testing service, including its use of next-generation sequencing to analyze cell-free DNA from a sample of maternal blood. Genoma's testing facility in Switzerland also services samples collected from its other labs, including those located in Spain and Italy.
Imaging Advantage LLC (IA), of Phoenix, reported the launch of a machine learning research initiative with faculty members from the Massachusetts Institute of Technology and Harvard Medical School/Massachusetts General Hospital, titled Singularity Healthcare . Singularity is developing an artificial intelligence engine to be incorporated into IA's proprietary exam routing technology, to instantly pre-read digital images and identify potential areas of injury and disease, while continuously learning from IA's expanding database of 7 billion images. The algorithm will be applied before images are routed to one of the 500 board certified radiologists connected in the cloud to IA's platform.
SES SA, of Luxembourg Germany, reported the deployment of Satmed, a satellite-based e-health platform, at the CURE Hospital for Children in Niger, to enhance health care in rural and remote regions in Niger. The Satmed e-health platform was conceived by SES Techcom Services, a subsidiary of SES, and is funded by the Luxembourg Government and the Ministry for Cooperation and Humanitarian Action. The satellite-based communication solution aims to improve public health in developing countries by enabling multiple medical applications and tools to operate collectively on a single platform.